Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Mounjaro (tirzepatide) has quickly become one of the most talked-about medications in the GLP-1 space. Unlike Ozempic and Wegovy which target only GLP-1 receptors, Mounjaro is a dual agonist — it activates both GLP-1 and GIP receptors, potentially making it more effective for weight loss.
How Does Mounjaro Work?
Tirzepatide mimics two natural gut hormones — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, these hormones help reduce appetite, slow gastric emptying, and improve insulin sensitivity.
Weight Loss Results
In clinical trials, participants taking the highest dose of tirzepatide (15mg) lost an average of 22.5% of their body weight over 72 weeks — significantly more than semaglutide-based medications. This has made Mounjaro highly sought after for weight management.
Availability and Cost
Mounjaro is FDA-approved for type 2 diabetes. Its weight-loss branded version, Zepbound, has been approved for chronic weight management. Monthly costs without insurance typically range from $900-$1,100.
Side Effects
- Nausea (most common, especially when starting)
- Diarrhea or constipation
- Decreased appetite
- Vomiting
- Stomach pain
Most side effects are mild to moderate and tend to improve as your body adjusts to the medication. Starting at a low dose and gradually increasing helps minimize side effects.
Mounjaro vs. Ozempic: Key Differences in 2026
Mounjaro (tirzepatide) differs from Ozempic (semaglutide) in one critical way: it activates two hormone receptors instead of one. Ozempic targets only GLP-1 receptors, while Mounjaro targets both GLP-1 and GIP receptors simultaneously. This dual mechanism has produced significantly greater weight loss results in clinical trials.
| Medication | Active Ingredient | Receptors Targeted | Avg Weight Loss | Monthly Cost (No Insurance) |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | GLP-1 + GIP | ~21% body weight | $1,000–$1,200 |
| Ozempic | Semaglutide | GLP-1 only | ~14% body weight | $900–$1,100 |
| Zepbound | Tirzepatide | GLP-1 + GIP | ~22.5% body weight | $1,000–$1,200 |
| Wegovy | Semaglutide | GLP-1 only | ~15% body weight | $1,300–$1,700 |
Mounjaro for Weight Loss: What the 2026 Data Shows
The SURMOUNT clinical trials established Mounjaro as the most effective GLP-1 class medication for weight loss among currently approved options. At the highest dose (15mg), participants lost an average of 21% of body weight over 72 weeks — roughly double the results seen with semaglutide at standard doses. For someone weighing 250 pounds, that represents a potential loss of 52 pounds.
In 2026, the real-world data has continued to align with the clinical trial results. Patients who remain consistent with weekly injections and maintain dietary changes tend to see the most significant outcomes.
Who Is Mounjaro Prescribed For?
Mounjaro was originally FDA-approved for type 2 diabetes management. Its sister drug Zepbound (same active ingredient, tirzepatide) carries FDA approval specifically for chronic weight management. In practice, many physicians prescribe Mounjaro off-label for weight loss in 2026, particularly for patients who have not achieved adequate results with semaglutide.
Typical candidates include adults with a BMI of 27 or higher with at least one weight-related condition, or a BMI of 30 or higher regardless of other conditions.
Mounjaro Side Effects to Know
The most common side effects of Mounjaro are gastrointestinal and mirror those seen with other GLP-1 medications:
- Nausea — most common during dose escalation phases, typically improves within 4–8 weeks
- Vomiting and diarrhea — more likely at higher doses; managed by slowing down dose escalation
- Constipation — particularly at higher doses; adequate hydration helps
- Reduced appetite — considered a therapeutic effect rather than a side effect by most patients
- Injection site reactions — mild bruising or redness at the injection site
Serious but rare risks include pancreatitis and thyroid tumors. Mounjaro carries a black box warning for thyroid C-cell tumors based on animal data, though this has not been confirmed in human clinical trials.
How to Get Mounjaro in 2026
Mounjaro requires a prescription from a licensed physician. Options include:
- In-person prescriber: Your primary care physician or endocrinologist can prescribe Mounjaro if you meet the criteria
- Telehealth services: Several telehealth platforms now offer Mounjaro prescriptions with online consultations, often with faster access and lower cost than traditional medical appointments
- Manufacturer savings card: Eli Lilly offers a savings program that can reduce out-of-pocket costs for eligible commercially insured patients
Frequently Asked Questions About Mounjaro
Is Mounjaro better than Ozempic for weight loss?
Clinical data consistently shows tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy). The SURMOUNT-1 trial showed 22.5% body weight reduction with tirzepatide 15mg versus approximately 14-15% with semaglutide at high doses. Individual results vary.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound contain the same active ingredient — tirzepatide — manufactured by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. The main practical difference is the FDA indication, which affects insurance coverage. Learn more in our GLP-1 insurance coverage guide.
Can you get compounded tirzepatide like compounded semaglutide?
As of 2026, compounded tirzepatide availability has changed significantly. Unlike compounded semaglutide, which became widely available during the Ozempic shortage, compounded tirzepatide has faced stricter regulatory scrutiny. Availability varies — consult with a telehealth provider for current options.
📚 Related Reading
Considering GLP-1 Medication?
Check eligibility for compounded semaglutide — the affordable alternative to brand-name Ozempic starting from $149/month. No insurance required.
Take the Free Eligibility Quiz →
Sponsored | Affiliate link | Not available in all states
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.
📋 Compare Top GLP-1 Providers — Find Your Best Option